Bacterial infections in patients with liver cirrhosis | CMAC

Bacterial infections in patients with liver cirrhosis

Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(4):284-295

​ Litvinchuk D.V., Danilov D.E., Solovey N.V., Karpov I.A.
bacterial infections liver cirrhosis spontaneous bacterial peritonitis pneumonia urinary tract infection antibacterial therapy
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(4):284-295

Abstract

Patients with liver cirrhosis are at substantial risk of bacterial infections. Bacterial complications account for more than 30% of hospitalizations and contribute significantly to mortality among cirrhotic patients. The most common bacterial infections in that patient population are spontaneous bacterial peritonitis, pneumonia, urinary tract infection, and skin and soft tissue infections. This article describes the key underlying pathophysiologic mechanisms predisposing cirrhotic patients to bacterial infections. Etiology of bacterial complications is presented. Specific inflammatory and immune responses in liver cirrhosis as well as clinical and laboratory signs of bacterial infections in cirrhotic patients are considered. Empiric antibacterial treatment regimens and principles of antimicrobial prophylaxis in patients with spontaneous bacterial peritonitis are also provided.

Dmitry V. Litvinchuk

Belorussian State Medical University, Minsk, Belarus

Danilov D.E.

Belorussian State Medical University, Minsk, Belarus

Solovey N.V.

Belorussian State Medical University, Minsk, Belarus

Igor A. Karpov

Belorussian State Medical University, Minsk, Belarus

  • 1. Borzio M., Salerno F., Piantoni L., et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001;33(1):41-48.
  • 2. Fernández J., Navasa M., Gómez J., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35(1):140-148.
  • 3. Tandon P., Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28(1):26-42.
  • 4. Fernández J., Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Suppl. 1):S1-12.
  • 5. Gustot T., Durand F., Lebrec D., Vincent J.-L., Moreau R. Severe sepsis in cirrhosis. Hepatology. 2009;50(6):2022-2033.
  • 6. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol. 2005;42 Suppl(1):S85-92.
  • 7. Arvaniti V., D’Amico G., Fede G., et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246-1256.
  • 8. Wong F., Bernardi M., Balk R., et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut. 2005;54(5):718-725.
  • 9. Merli M., Lucidi C., Giannelli V., et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010;8(11):979-985.
  • 10. Foreman M.G., Mannino D.M., Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest. 2003;124(3):1016-1020.
  • 11. Fasolato S., Angeli P., Dallagnese L., et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007;45(1):223-229.
  • 12. Moreau R., Jalan R., Gines P., et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437.
  • 13. Bernard B., Grangé J.D., Khac E.N., et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29(6):1655-1661.
  • 14. Sedman P.C., Macfie J., Sagar P., et al. The prevalence of gut translocation in humans. Gastroenterology. 1994;107(3):643-649.
  • 15. Garcia-Tsao G., Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol. 2004;18(2):353-372.
  • 16. Runyon B.A., Squier S., Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol. 1994;21(5):792-796.
  • 17. Wiest R., Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41(3):422-433.
  • 18. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268-1273.
  • 19. Thalheimer U. Infection, coagulation, and variceal bleeding in cirrhosis. Gut. 2005;54(4):556-563.
  • 20. Guarner C., Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2005;17(1):27-31.
  • 21. Chan C.C., Hwang S.J., Lee F.Y., et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol. 1997;32(9):942946.
  • 22. Bellot P., García-Pagán J.C., Francés R., et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52(6):2044-2052.
  • 23. Bajaj J.S., Hylemon P.B., Ridlon J.M., et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303(6):G675-685.
  • 24. Chen Y., Yang F., Lu H., et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562572.
  • 25. Teltschik Z., Wiest R., Beisner J., et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology. 2012;55(4):1154-1163.
  • 26. Yan A.W., Fouts D.E., Brandl J., et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology. 2011;53(1):96-105.
  • 27. Pande C., Kumar A., Sarin S.K. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther. 2009;29(12):1273-1281.
  • 28. Kalambokis G.N., Tsianos E.V. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology. 2012;55(2):655-656.
  • 29. Madrid A.M., Hurtado C., Venegas M., Cumsille F., Defilippi C. LongTerm treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol. 2001;96(4):1251-1255.
  • 30. Iadevaia M.D., Prete A.D., Cesaro C., et al. Rifaximin in the treatment of hepatic encephalopathy. Hepat Med. 2011;3:109-117.
  • 31. Marchese A., Salerno A., Pesce A., Debbia E.A., Schito G.C. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammoniaproducing species. Chemotherapy. 2000;46(4):253-266.
  • 32. Goral V., Atayan Y., Kaplan A. The relation between pathogenesis of liver cirrhosis, hepatic encephalopathy and serum cytokine levels: what is the role of tumor necrosis factor α? Hepatogastroenterology. 2011;58(107108):943-948.
  • 33. Assimakopoulos S.F., Tsamandas A.C., Tsiaoussis G.I., et al. Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest. 2012;42(4):439-446.
  • 34. Yu L.C. Commensal bacterial internalization by epithelial cells: An alternative portal for gut leakiness. Tissue Barriers. 2015;3(3):e1008895.
  • 35. Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3(4):759-791.
  • 36. Tritto G., Bechlis Z., Stadlbauer V., et al. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol. 2011;55(3):574581.
  • 37. Wasmuth H.E., Kunz D., Yagmur E., et al. Patients with acute on chronic liver failure display ‘sepsis-like’ immune paralysis. J Hepatol. 2005;42(2):195201.
  • 38. Fiuza C., Salcedo M., Clemente G., Tellado J.M. In Vivo Neutrophil Dysfunction in Cirrhotic Patients with Advanced Liver Disease. J Infect Dis. 2000;182(2):526-533.
  • 39. Christou L., Pappas G., Falagas M.E. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol. 2007;102(7):1510-1517.
  • 40. Xu R., Huang H., Zhang Z., Wang F.S. The role of neutrophils in the development of liver diseases. Cell Mol Immunol. 2014;11(3):224-231.
  • 41. Albillos A., Lario M., Álvarez-Mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385-1396.
  • 42. Parrow N.L., Fleming R.E., Minnick M.F. Sequestration and scavenging of iron in infection. Infect Immun. 2013;81(10):3503-3514.
  • 43. Khan F.A., Fisher M.A., Khakoo R.A. Association of hemochromatosis with infectious diseases: expanding spectrum. Int J Infect Dis. 2007;11(6):482487.
  • 44. Porto G. Iron overload and immunity. World J Gastroenterol. 2007;13(35):4707-4715.
  • 45. Bruns T., Peter J., Reuken P.A., et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int. 2012;32(2):223-230.
  • 46. Nischalke H.D., Berger C., Aldenhoff K., et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol. 2011;55(5):1010-1016.
  • 47. Appenrodt B., Grünhage F., Gentemann M.G., et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology. 2010;51(4):1327-1333.
  • 48. Shawcross D.L., Wright G.A., Stadlbauer V., et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology. 2008;48(4):1202-1212.
  • 49. Gao B., Jeong W.I., Tian Z. Liver: An organ with predominant innate immunity. Hepatolology. 2008;47(2):729-736.
  • 50. Katz S., Jimenez M.A., Lehmkuhler W.E., Grosfeld J.L. Liver bacterial clearance following hepatic artery ligation and portacaval shunt. J Surg Res. 1991;51(3):267-270.
  • 51. Francés R., Benlloch S., Zapater P., et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology. 2004;39(2):484-491.
  • 52. Frances R. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut. 2004;53(6):860-864.
  • 53. Vincent J.L., Gustot T. Sepsis and cirrhosis: many similarities. Acta Gastroenterol Belg. 2010;73(4):472-478.
  • 54. Cazzaniga M., Dionigi E., Gobbo G., et al. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol. 2009;51(3):475-482.
  • 55. Park W.B., Lee K.D., Lee C.S., et al. Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. Diagn Microbiol Infect Dis. 2005;51(4):227-230.
  • 56. Tsiakalos A., Karatzaferis A., Ziakas P., Hatzis G. Acute-phase proteins as indicators of bacterial infection in patients with cirrhosis. Liver Int. 2009;29(10):1538-1542.
  • 57. Li C.H., Yang R.B., Pang J.H., et al. Procalcitonin as a biomarker for bacterial infections in patients with liver cirrhosis in the emergency department. Acad Emerg Med. 2011;18(2):121-126.
  • 58. Cervoni J.-P., Thévenot T., Weil D., et al. C-Reactive protein predicts shortterm mortality in patients with cirrhosis. J Hepatol. 2012;56(6):1299-1304.
  • 59. Yang Y., Li L., Qu C., et al. Diagnostic Accuracy of Serum Procalcitonin for Spontaneous Bacterial Peritonitis Due to End-stage Liver Disease: A Metaanalysis. Medicine (Baltimore). 2015;94(49):e2077.
  • 60. Qu J., Feng P., Luo Y., Lü X. Impact of hepatic function on serum procalcitonin for the diagnosis of bacterial infections in patients with chronic liver disease: A retrospective analysis of 324 cases. Medicine (Baltimore). 2016;95(30):e4270.
  • 61. Cai Z.-H., Fan C.-L., Zheng J.-F., et al. Measurement of serum procalcitonin levels for the early diagnosis of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis. BMC Infect Dis. 2015;15:55.
  • 62. Meisner M. Update on Procalcitonin Measurements. Ann Lab Med. 2014;34(4):263-273.
  • 63. Akalin H.E., Laleli Y., Telatar H. Bactericidal and opsonic activity of ascitic fluid from cirrhotic and noncirrhotic patients. J Infect Dis. 1983;147(6):1011-1017.
  • 64. Ozmen S., Dursun M., Yilmaz S. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Acta Gastroenterol Belg. 2006;69(3):276-282.
  • 65. Cheong H.S., Kang C., Lee J.A., et al. Clinical Significance and Outcome of Nosocomial Acquisition of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis. Clin Infect Dis. 2009;48(9):1230-1236.
  • 66. Hong W., Zhu Q., Huang Z., et al. Predictors of esophageal varices in patients with HBV-related cirrhosis: a retrospective study. BMC Gastroenterol. 2009;9:11.
  • 67. Alaniz C., Regal R.E. Spontaneous bacterial peritonitis: a review of treatment options. P T. 2009;34(4):204-210.
  • 68. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.
  • 69. Dever J.B., Sheikh M.Y. Review article: spontaneous bacterial peritonitis – bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015;41(11):1116-1131.
  • 70. Runyon B.A., AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651-1653.
  • 71. Pelletier G., Salmon D., Ink O., et al. Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis. J Hepatol. 1990;10(3):327-331.
  • 72. Nguyen-Khac E., Cadranel J.F., Thevenot T., Nousbaum J.B. Review article: the utility of reagent strips in the diagnosis of infected ascites in cirrhotic patients. Aliment Pharmacol Ther. 2008;28(3):282-288.
  • 73. Sapey T., Mena E., Fort E., et al. Rapid diagnosis of spontaneous bacterial peritonitis with leukocyte esterase reagent strips in a European and in an American center. J Gastroenterol Hepatol. 2005;20(2):187-192.
  • 74. Fiore M., Maraolo A.E., Gentile I., et al. Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review. World J Gastroenterol. 2017;23(25):4654-4660.
  • 75. Jalan R., Fernandez J., Wiest R., et al. Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310-1324.
  • 76. Follo A., Llovet J.M., Navasa M., et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20(6):1495-1501.
  • 77. Kwok C.S., Krupa L., Mahtani A., et al. Albumin reduces paracentesisinduced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and metaanalysis. Biomed Res Int. 2013;2013:295153.
  • 78. Chen T.-A., Tsao Y.-C., Chen A., et al. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol. 2009;44(5):619-625.
  • 79. Terg R., Gadano A., Cartier M., et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int. 2009;29(3):415-419.
  • 80. Wang J.-L., Hsueh P.-R. Therapeutic options for infections due to vancomycinresistant enterococci. Expert Opin Pharmacother. 2009;10(5):785-796.
  • 81. Piano S., Fasolato S., Salinas F., et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. Hepatology. 2016;63(4):1299-1309.
  • 82. Niwa T., Suzuki A., Sakakibara S., et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126-2133.
  • 83. García-Tsao G. Further evidence against the use of aminoglycosides in cirrhotic patients. Gastroenterology. 1998;114(3):612-613.
  • 84. Titó L., Rimola A., Ginès P., et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology. 1988;8(1):27-31.
  • 85. Ginés P., Rimola A., Planas R., et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12(4 Pt 1):716-724.
  • 86. Cohen M.J., Sahar T., Benenson S., et al. Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev. 2009;(2):CD004791.
  • 87. Loomba R., Wesley R., Bain A., Csako G., Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: metaanalysis. Clin Gastroenterol Hepatol. 2009;7(4):487-493.
  • 88. Soriano G., Castellote J., Alvarez C., et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol. 2010;52(1):39-44.
  • 89. Friedman L.S. Surgery in the patient with liver disease. Trans Am Clin Climatol Assoc. 2010;121:192-204; discussion 205.
  • 90. Lin Y.-T., Wu P.-H., Lin C.-Y., et al. Cirrhosis as a Risk Factor for Tuberculosis Infection – A Nationwide Longitudinal Study in Taiwan. Am J Epidemiol. 2014;180(1):103-110.
  • 91. Srivastava U., Almusa O., Tung K., Heller M.T. Tuberculous peritonitis. Radiol Case Rep. 2014;9(3):971.
  • 92. Sanai F.M., Bzeizi K.I. Systematic review: tuberculous peritonitis – presenting features, diagnostic strategies and treatment. Aliment Pharmacol Ther. 2005;22(8):685-700.
  • 93. Kim N.J., Choo E.J., Kwak Y.G., et al. Tuberculous peritonitis in cirrhotic patients: comparison of spontaneous bacterial peritonitis caused by Escherichia coli with tuberculous peritonitis. Scand J Infect Dis. 2009;41(11-12):852-856.
  • 94. Menke J., Kühnle I. Tuberculous peritonitis with infracarinal mass and elevated CA-125 in a 13-year-old girl. Infection. 2014;42(2):415-418.
  • 95. Bae S.Y., Lee J.H., Park J.Y., et al. Clinical significance of serum CA-125 in Korean females with ascites. Yonsei Med J. 2013;54(5):1241-1247.
  • 96. Kim E.S., Park K.U., Song J., et al. The clinical significance of CA-125 in pulmonary tuberculosis. Tuberculosis (Edinb). 2017;107:104-110.
  • 97. Kumar N. Antitubercular therapy in patients with cirrhosis: Challenges and options. World J Gastroenterol. 2014;20(19):5760-5772.
  • 98. Chen C.-H., Shih C.-M., Chou J.-W., et al. Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver Int. 2011;31(3):417424.
  • 99. Lam S.T., Johnson M.L., Kwok R.M., Bassett J.T. Spontaneous bacterial empyema: not your average empyema. Am J Med. 2014;127(7):e9-10.
  • 100. Roussos A., Philippou N., Mantzaris G.J., Gourgouliannis K.I. Hepatic hydrothorax: pathophysiology diagnosis and management. J Gastroenterol Hepatol. 2007;22(9):1388-1393.
  • 101. Bunchorntavakul C. Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol. 2012;4(5):158-168.
  • 102. Cruz Rde C.R., Tanajura D., Almeida D., Cruz M., Paraná R. Urinary tract infection in non-hospitalized patients with cirrhosis and no symptoms of urinary tract infection: a case series study. Braz J Infect Dis. 2006;10(6):380383.
  • 103. Ye C., Kumar D., Carbonneau M., et al. Asymptomatic bacteriuria is an independent predictor of urinary tract infections in an ambulatory cirrhotic population: a prospective evaluation. Liver Int. 2014;34(6):e39-44.
  • 104. Reuken P.A., Stallmach A., Bruns T. Mortality after urinary tract infections in patients with advanced cirrhosis – Relevance of acute kidney injury and comorbidities. Liver Int. 2013;33(2):220-230.
  • 105. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl. 1A):5S-13S.
  • 106. Sanchez G.V., Babiker A., Master R.N., et al. Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016;60(5):2680-2683.
  • 107. Jancel T., Dudas V. Management of uncomplicated urinary tract infections. West J Med. 2002;176(1):51-55.
  • 108. Al-Osaimi A., Manne V., Sundaram V. Ascites and spontaneous bacterial peritonitis: Recommendations from two United States centers. Saudi J Gastroenterol. 2014;20(5):279-287.
  • 109. Kang C.-I., Cha M.K., Kim S.H., et al. Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum β-lactamaseproducing Escherichia coli over a 6-year period. J Korean Med Sci. 2013;28(7):998-1004.
  • 110. Hung T.-H., Tseng C.-W., Hsieh Y.-H., et al. High mortality of pneumonia in cirrhotic patients with ascites. BMC Gastroenterol. 2013;13:25.
  • 111. Viasus D., Garcia-Vidal C., Castellote J., et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine (Baltimore). 2011;90(2):110-118.
  • 112. Propst-Graham K.L., Preheim L.C., Vander Top E.A., Snitily M.U., GentryNielsen M.J. Cirrhosis-induced defects in innate pulmonary defenses against Streptococcus pneumoniae. BMC Microbiol. 2007;7(1):94.
  • 113. Alcantara R.B., Preheim L.C., Gentry-Nielsen M.J. Pneumolysin-Induced Complement Depletion during Experimental Pneumococcal Bacteremia. Infect Immun. 2001;69(6):3569-3575.
  • 114. Falguera M., Trujillano J., Caro S., et al. A Prediction Rule for Estimating the Risk of Bacteremia in Patients with Community-Acquired Pneumonia. Clin Infect Dis. 2009;49(3):409-416.
  • 115. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis. 2007;44(Suppl. 2):S27-72.
  • 116. Neff G.W., Duncan C.W., Schiff E.R. The current economic burden of cirrhosis. Gastroenterol Hepatol. 2011;7(10):661-671.
  • 117. Marrie T.J., Tyrrell G.J., Majumdar S.R., Eurich D.T. Concurrent Infection with Hepatitis C Virus and Streptococcus pneumoniae. Emerg Infect Dis. 2017;23(7):1118-1123.
  • 118. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating hepatitis C. Hepatology. 2015;62(3):932-954.
  • 119. Wu H.-P., Chu C.-M., Lin C.-Y., et al. Liver Cirrhosis and Diabetes Mellitus Are Risk Factors for Staphylococcus aureus Infection in Patients with Healthcare-Associated or Hospital-Acquired Pneumonia. Pulm Med. 2016;2016:1-6.
  • 120. Kalil A.C., Metersky M.L., Klompas M., et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-111.
  • 121. Fernández J., Acevedo J., Castro M., et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55(5):1551-1561.
  • 122. Hamza R.E., Villyoth M.P., Peter G., et al. Risk factors of cellulitis in cirrhosis and antibiotic prophylaxis in preventing recurrence. Ann Gastroenterol. 2014;27(4):374-379.
  • 123. Lin M.-N., Tsai C.-C., Hung T.-H., Tsai C.-C. The Risk of Cellulitis in Cirrhotic Patients: A Nationwide Population-Based Study in Taiwan. Gut Liver. 2012;6(4):482-485.
  • 124. Mohan P., Ramu B., Bhaskar E., Venkataraman J. Prevalence and risk factors for bacterial skin infection and mortality in cirrhosis. Ann Hepatol. 2011;10(1):15-20.
  • 125. Horowitz Y., Sperber A.D., Almog Y. Gram-Negative Cellulitis Complicating Cirrhosis. Mayo Clin Proc. 2004;79(2):247-250.
  • 126. Liu B.-M., Chung K.-J., Chen C.-H., et al. Risk factors for the outcome of cirrhotic patients with soft tissue infections. J Clin Gastroenterol. 2008;42(3):312-316.
  • 127. Rongey C., Runyon B.A. Cellulitis in Patients with Cirrhosis and Edema: An Under-Recognized Complication Currently More Common than Spontaneous Bacterial Peritonitis. Open Gastroenterol J. 2008;2(1):24-27.
  • 128. Chang C.-M., Lee H.-C., Lee N.-Y., et al. Community-acquired Klebsiella pneumoniae complicated skin and soft-tissue infections of extremities: emphasis on cirrhotic patients and gas formation. Infection. 2008;36(4):328-334.
  • 129. Corredoira J.M., Ariza J., Pallarés R., et al. Gram-negative bacillary cellulitis in patients with hepatic cirrhosis. Eur J Clin Microbiol Infect Dis. 1994;13(1):19-24.
  • 130. Hung T.-H., Tsai C.-C., Tsai C.-C., Tseng C.-W., Hsieh Y.-H. Liver cirrhosis as a real risk factor for necrotising fasciitis: a three-year population-based follow-up study. Singapore Med J. 2014;55(7):378-382.
  • 131. Horseman M.A., Surani S. A comprehensive review of Vibrio vulnificus: an important cause of severe sepsis and skin and soft-tissue infection. Int J Infect Dis. 2011;15(3):e157-166.
  • 132. Sartor C., Bornet C., Guinard D., Fournier P.-E. Transmission of Aeromonas hydrophila by leeches. Lancet. 2013;381(9878):1686.
  • 133. Igbinosa I.H., Igumbor E.U., Aghdasi F., Tom M., Okoh AI. Emerging Aeromonas Species Infections and Their Significance in Public Health. Sci World J. 2012;2012:1-13.
  • 134. Aravena-Román M., Inglis T.J., Henderson B., Riley T.V., Chang B.J. Antimicrobial susceptibilities of Aeromonas strains isolated from clinical and environmental sources to 26 antimicrobial agents. Antimicrob Agents Chemother. 2012;56(2):1110-1112.
  • 135. Migliore E., Serraino C., Brignone C., et al. Pasteurella multocida infection in a cirrhotic patient: case report, microbiological aspects and a review of literature. Adv Med Sci. 2009;54(1):109-112.
  • 136. Hung T.-H., Hsieh Y.-H., Tseng K.-C., Tsai C.-C., Tsai C.-C. The risk for bacterial endocarditis in cirrhotic patients: a population-based 3-year follow-up study. Int J Infect Dis. 2013;17(6):e391-393.
  • 137. Fernández Guerrero M.L., González López J., Górgolas M. Infectious endocarditis in patients with cirrhosis of the liver: a model of infection in the frail patient. Eur J Clin Microbiol Infect Dis. 2010;29(10):1271-1275.
  • 138. Hsu R.-B., Chen R.J., Chu S.-H. Infective endocarditis in patients with liver cirrhosis. J Formos Med Assoc. 2004;103(5):355-358.
  • 139. Baddour L.M., Wilson W.R., Bayer A.S., et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):14351486.
  • 140. Mølle I., Thulstrup A.M., Svendsen N., Schønheyder H.C., Sørensen H.T. Risk and case fatality rate of meningitis in patients with liver cirrhosis. Scand J Infect Dis. 2000;32(4):407-410.
  • 141. Pagliano P., Boccia G., De Caro F., Esposito S. Bacterial meningitis complicating the course of liver cirrhosis. Infection. 2017;45(6):795-800.
  • 142. Cabellos C., Viladrich P.F., Ariza J., et al. Community-acquired bacterial meningitis in cirrhotic patients. Clin Microbiol Infect. 2008;14(1):35-40.
  • 143. Chang W.-N., Huang C.-R., Lu C.-H., Chien C.-C. Adult Klebsiella pneumoniae meningitis in Taiwan: an overview. Acta Neurol Taiwanica. 2012;21(2):87-96.
  • 144. Shih H.-I., Lee H.-C., Chuang C.-H., Ko W.-C. Fatal Klebsiella pneumoniae Meningitis and Emphysematous Brain Abscess After Endoscopic Variceal Ligation in a Patient with Liver Cirrhosis and Diabetes Mellitus. J Formos Med Assoc. 2006;105(10):857-860.
  • 145. van de Beek D., Cabellos C., Dzupova O., et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22:S37-62.
  • 146. Kim J.H., Lee J.S., Lee S.H., et al. Renal Dysfunction Induced by Bacterial Infection other than Spontaneous Bacterial Peritonitis in Patients with Cirrhosis: Incidence and Risk Factor. Gut Liver. 2009;3(4):292-297.
  • 147. Chen Y.-C., Hung T.H., Tseng K.C., et al. Increased occurrence of brain abscesses in cirrhotic patients: A population-based 3-year follow-up study. Turk J Gastroenterol. 2017;28(5):342-346.
  • 148. Brouwer M.C., Tunkel A.R., McKhann G.M., van de Beek D. Brain abscess. N Engl J Med. 2014;371(5):447-456.
  • 149. Chen C.-C., Hsu P.-W., Lee S.-T., et al. Brain surgery in patients with liver cirrhosis: Clinical article. J Neurosurg. 2012;117(2):348-353.
  • 150. Taneja S.K., Dhiman R.K. Prevention and Management of Bacterial Infections in Cirrhosis. Int J Hepatol. 2011;2011:1-7.
  • 151. Goulis J., Patch D., Burroughs A.K. Bacterial infection in the pathogenesis of variceal bleeding. Lancet. 1999;353(9147):139-142.
  • 152. Kate V., Kumar S., Sadasivan J., Agarwal A. Antibiotic prophylaxis in the prevention of rebleeding in acute variceal hemorrhage: A randomized trial. J Pharmacol Pharmacother. 2015;6(1):24-29.
  • 153. Moon A.M., Dominitz J.A., Ioannou G.N., Lowy E., Beste L.A. Use of Antibiotics Among Patients With Cirrhosis and Upper Gastrointestinal Bleeding Is Associated With Reduced Mortality. Clin Gastroenterol Hepatol. 2016;14(11):1629-1637.e1.
  • 154. Garcia-Tsao G., Surawicz C.M. Editorial: Clostridium difficile Infection: Yet Another Predictor of Poor Outcome in Cirrhosis. Am J Gastroenterol. 2010;105(1):114-116.
  • 155. Bajaj J.S., Ananthakrishnan A.N., Hafeezullah M., et al. Clostridium difficile Is Associated With Poor Outcomes in Patients With Cirrhosis: A National and Tertiary Center Perspective. Am J Gastroenterol. 2010;105(1):106113.
  • 156. Senzolo M., Cholongitas E., Burra P., et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009;29(8):1189-1193.
  • 157. Ferrarese A., Zanetto A., Germani G., Burra P., Senzolo M. Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol. 2016;8(24):1012-1018.
  • 158. Sersté T., Melot C., Francoz C., et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52(3):1017-1022.
  • 159. De Backer D., Orbegozo Cortes D., Donadello K., Vincent J.-L. Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock. Virulence. 2014;5(1):73-79.
  • 160. Ruiz-del-Arbol L., Urman J., Fernández J., et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38(5):1210-1218.
  • 161. Dhiman R.K. Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome. World J Gastroenterol. 2014;20(40):14934.
  • 162. Theocharidou E., Pieri G., Mohammad A.O., et al. The Royal Free Hospital Score: A Calibrated Prognostic Model for Patients With Cirrhosis Admitted to Intensive Care Unit. Comparison With Current Models and CLIF-SOFA Score. Am J Gastroenterol. 2014;109(4):554-562.
  • 163. Sun D.-Q., Zheng C.-F., Liu W.-Y., et al. AKI-CLIF-SOFA: a novel prognostic score for critically ill cirrhotic patients with acute kidney injury. Aging. 2017;9(1):286-296.
  • 164. López-Velázquez J.A., Chávez-Tapia N.C., Ponciano-Rodríguez G., et al. Bilirubin alone as a biomarker for short-term mortality in acute-onchronic liver failure: an important prognostic indicator. Ann Hepatol. 2013;13(1):98-104.
  • 165. Arabi Y., Ahmed Q.A.A., Haddad S., Aljumah A., Al-Shimemeri A. Outcome predictors of cirrhosis patients admitted to the intensive care unit. Eur J Gastroenterol Hepatol. 2004;16(3):333-339.
  • 166. Tsai M.-H., Peng Y.-S., Chen Y.-C., et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43(4):673-681.
  • 167. Fernández J., Escorsell A., Zabalza M., et al. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology. 2006;44(5):1288-1295.
  • 168. Sauneuf B., Champigneulle B., Soummer A., et al. Increased survival of cirrhotic patients with septic shock. Crit Care. 2013;17(2):R78.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared